Merck, a leading science and technology company, has launched its AIDDISON™ drug discovery software, the first software-as-a-service platform that bridges the gap between virtual molecule design and real-world manufacturability through SynthiaTM retrosynthesis software application programing interface (API) integration.
It combines generative AI, machine learning and computer-aided drug-design to speed up drug development. Trained on more than two decades of experimentally validated datasets from pharmaceutical R&D, AIDDISON™ software identifies compounds from over 60 billion possibilities that have key properties of a successful drug, such as non-toxicity, solubility, and stability in the body. The platform then proposes ways to best synthesize these drugs.
Discovering drugs is a long, iterative process. Only about 10% of drug candidates evaluated in Phase I made it to market. To find the most suitable chemical compound from a universe of more than 1060 molecules requires significant time, resources, and expertise.
Artificial Intelligence (AI) and machine learning models like AIDDISON™ software can extract hidden insights from huge datasets, thus increasing the success rate of delivering new therapies to patients. AI has the potential to offer more than $70 billion in savings for the drug discovery process by 2028, and to save up to 70% time and costs for drug discovery in pharmaceutical companies.
